Current Report Filing (8-k)
10 Fevereiro 2023 - 9:31AM
Edgar (US Regulatory)
0001402328
false
0001402328
2023-02-07
2023-02-07
0001402328
us-gaap:CommonStockMember
2023-02-07
2023-02-07
0001402328
SBFM:CommonStockPurchaseWarrantsMember
2023-02-07
2023-02-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Form
8-K
Current Report Pursuant to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
February
7, 2023
SUNSHINE
BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
| Colorado |
001-41282 |
20-5566275 |
|
(State or other jurisdiction
of incorporation) |
(Commission File Number) |
(IRS Employer ID No.) |
6500 Trans-Canada Highway
4th Floor
Pointe-Claire, Quebec, Canada H9R0A5
(Address of principal executive offices) (zip
code)
(514) 426-6161
(Registrant’s telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Act:
| Title of Each Class |
Trading Symbol |
Name of Each Exchange on Which Registered |
| Common Stock, par value $0.001 |
SBFM |
The Nasdaq
Stock Market LLC |
| Common Stock Purchase Warrants |
SBFMW |
The Nasdaq
Stock Market LLC |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 1.01. |
Entry into a Material Definitive Agreement. |
On February 7, 2023,
Sunshine Biopharma, Inc. (the “Company”) received a duly executed research agreement (the “Research Agreement”)
with Sir Mortimer B. Davis Jewish General Hospital, a McGill University Health Center hospital located in Montreal, Quebec, Canada (“JGH”)
in connection with the Company’s Adva-27a anticancer compound. The research effort will be focused on advancing the development
of the Company’s Adva-27a anticancer compound through the IND-enabling studies. In the event that the research results are conclusive
and the Company determines that it wishes to conduct a Phase I clinical trial on the Adva-27a molecule, the parties agree to negotiate
an agreement to determine the responsibilities and obligations of the parties for such Phase I clinical trial.
All improvements, changes or modifications to
the Adva-27a molecule, including the research results obtained during the term of the Research Agreement shall remain the exclusive property
of the Company. The Research Agreement is for a term of three (3) years and the Company has agreed to pay JGH the fair market value for
the services to be rendered in an amount agreed upon by the parties. The Company has also agreed to pay JGH a 3% royalty for a period
of 20 years on all net revenues it generates from the use of the intellectual property arising during the term of the Research Agreement.
The foregoing description of the Research Agreement
is qualified by reference to the full text of the Research Agreement which is filed as an exhibit to this report.
| Item 7.01 | Regulation FD Disclosure |
A press release being issued by the Company following
the filing of this report which announces the Research Agreement between the Company and JGH is attached as Exhibit 99.1.
In accordance with General Instruction B.2 of
Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under
the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01 |
Financial Statements and Exhibits. |
(b) Exhibits. The following exhibits are included
in this report:
*Annexes of this agreement have been omitted.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| Dated: February 10, 2023 |
SUNSHINE BIOPHARMA, INC. |
| |
(Registrant) |
| |
|
| |
By: /s/ Dr. Steve N. Slilaty |
| |
Dr. Steve N. Slilaty, Chief Executive Officer |
Sunshine Biopharma (NASDAQ:SBFM)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Sunshine Biopharma (NASDAQ:SBFM)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
